Tell us about your product.
We will tell you whether it can win in the GCC.
Including when the answer is no. A clear no in three weeks is worth more to you than an optimistic yes and eighteen months of registration cost.
Who we are
Shifa Medical Solutions is a private company based in Muscat, Sultanate of Oman. We are a business development company: product selection, registration, marketing, sales, medical affairs and distribution, carried out for pharmaceutical manufacturers who want a position in the GCC and the wider Middle East and Africa.
We work for manufacturers, not against them. We hold no competing portfolio of our own, and we do not represent two products in the same therapeutic position.
Opal Bio Pharma is our partner and an investor in Shifa. That relationship gives us an approved CDMO site inside the GCC and the operating experience of a company that has taken products through GCC registration itself. The two are separate legal entities.
Where we do our best work.
Four areas where we have the people, the relationships and the track record to move a product forward.
Biosimilars & Biologics
Registering and launching biosimilar therapies for immunology, nephrology and diabetes — giving hospitals a quality-assured, cost-effective alternative to originator biologics.
CDMO
Contract development and manufacturing at an approved GMP site in the GCC, so a product can qualify for local-production price preferences — without building or owning a plant.
Distribution & Market Access
Import, customs clearance, validated cold chain, stock cover and recall readiness — plus the pricing and tender strategy that gets a product in front of the right buyers.
Chemicals & Supplements
Sourcing and supplying pharmaceutical-grade chemicals and nutritional supplements from qualified manufacturers — with the documentation, registration and quality checks each GCC market requires.
What makes us different.
We work for manufacturers
We hold no competing portfolio of our own. We do not represent two products in the same therapeutic position.
We say no quickly
A clear no in three weeks is worth more to you than an optimistic yes and eighteen months of registration cost.
One partner, six services
Product selection, registration, marketing, medical affairs and distribution — under one accountable partner.
CDMO, today
An approved GMP site for CDMO inside the GCC, through our partner Opal Bio Pharma — already operating, not a plan.
What happens after you write.
A clear process, step by step.
We reply
If your product is outside what we can do well, we say so immediately rather than arrange a meeting about it.
A 30-minute call
The product, where it is approved, your price expectation and your timeline.
A written assessment
Competitive landscape in the GCC and MEA, achievable price band, volume estimate, regulatory route, and whether a CDMO route would improve the economics.
We move forward
If both sides want to proceed, we move to agency terms. If not, the assessment is yours to keep, at no cost.
What to send
The more detail you share upfront, the more useful our assessment can be.
Product details
Product name, molecule, strength and presentation.
Approval status
Countries where it is approved, and by which authority.
Manufacturing
Manufacturing site and its GMP status.
Indicative pricing
Ex-works price, if available at this stage.
Your goal in the region
Registration only, full commercialisation, or finding a CDMO.
Timeline
When you want to be in market, and any internal deadlines.
We will sign a confidentiality agreement before you send anything sensitive. Ask, and we will send ours — or we will sign yours.
Frequently asked questions
It depends on the product and on the requirements of each GCC market at the time of filing. We set this out in writing before submission, including what happens to the registration if the relationship ends.
Typically ten to eighteen months in the GCC, depending on product class and dossier completeness. We give a product-specific projection after the assessment, and we do not promise approval dates.
The GCC is our base. Beyond it, we cover more than 30 markets across the Middle East and Africa. Expansion is agreed product by product and market by market, and we will be straightforward about what is already in place and what would need to be built.
The initial assessment is at our cost. Beyond that, terms depend on scope and are agreed in writing before any work begins.
Start the conversation
We reply to every partnership enquiry within three working days.
Thank you — your enquiry has reached us.
A member of the team will reply within three working days. If your message concerns a suspected side effect, please also use our adverse event reporting route so that it is recorded correctly.
Looking to build a career in pharma, not just a job?
We are always interested in meeting people who want to help manufacturers bring quality medicines to the GCC and the wider Middle East and Africa — regulatory, commercial, medical affairs and operations.
Reach the right team
No. 356, Dauhat Al Adab St., Bawshar, Muscat, Sultanate of Oman · +968 7170 3120 · Sunday–Thursday (GMT+4)